Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2023-04-25 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
2022年年度股东大会之法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening and procedures of the 2022 Annual General Meeting (AGM) of the company 福安药业（集团）股份有限公司. It details the notice, agenda, voting procedures, and results of the 2022 AGM, confirming compliance with relevant laws and company rules. The document does not contain the actual annual report, audit report, or financial statements but rather discusses the AGM process and resolutions passed. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the AGM. The document length is about 5,219 characters, consistent with a detailed AGM legal opinion and voting results summary, not a full annual report or audit report. Therefore, the correct classification is AGM Information (AGM-R).
2023-04-25 Chinese
关于子公司收到药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (764 characters) about a subsidiary receiving a drug registration certificate from the National Medical Products Administration (国家药品监督管理局). It contains no financial statements or detailed financial data, only information about regulatory approval of a product. The document is an official announcement of a regulatory event related to product registration, not a financial report or detailed management discussion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a certification or voting result. Given the nature and length, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other categories.
2023-04-20 Chinese
关于变更2022年年度股东大会召开地点的公告
AGM Information Classification · 95% confidence The document is an announcement regarding the change of venue for the 2022 Annual General Meeting (AGM) of 福安药业 (Fuan Pharmaceutical Group Co., Ltd.). It details the new location, voting procedures including onsite and online voting, the agenda items to be discussed and voted on at the AGM, and instructions for shareholder registration and proxy voting. The document does not contain the actual annual report, audit report, or financial statements but rather information about the AGM logistics and agenda. Therefore, it fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting or announcements related to it. The document length is about 4928 characters, which is consistent with a detailed AGM announcement rather than a full annual report or audit report. Hence, the classification is AGM-R with high confidence.
2023-04-14 Chinese
2022年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the '2022年度监事会工作报告' which translates to '2022 Supervisory Board Work Report' of the company. It details the supervisory board's activities, meetings, and oversight of company operations, financials, internal controls, and compliance during the year 2022. It is a report from the supervisory board rather than a full annual report or audit report. It does not contain full financial statements or detailed audit opinions but rather a summary of supervisory activities and opinions on company governance and financial oversight. This fits the category of a Management Report (MDA), which includes management's explanation and oversight reports on company operations and financial results. The document length is 2071 characters, which is consistent with a detailed report but not a full annual report or audit report. Therefore, the best classification is Management Reports (MDA).
2023-03-30 Chinese
关于2022年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2022 annual profit distribution plan of the company 福安药业（集团）股份有限公司. It details the proposed cash dividend per share, total dividend amount, and references the approval process including board and supervisory meetings. The document does not contain full financial statements or comprehensive financial performance data but focuses on dividend distribution details. It is relatively short (1178 characters) and serves as an official announcement to shareholders about dividend amounts and related approvals. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2023-03-30 Chinese
2022年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the fiscal year ending December 31, 2022, issued by the board of 福安药业（集团）股份有限公司. It discusses the company's internal control effectiveness, scope, evaluation standards, and conclusions about the absence of major deficiencies in financial and non-financial internal controls. The content is detailed and substantive, covering internal control policies, risk assessments, and governance structures. It is not an announcement or a brief summary but a full report on internal control evaluation. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and internal control evaluations, excluding full annual reports. The document length (7311 characters) and detailed content support this classification with high confidence. FY 2022
2023-03-30 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.